Continuous versus targeted medication in schizophrenic outpatients: outcome results [published erratum appears in Am J Psychiatry 1991 Jun;148(6):819]

William T. Carpenter, Thomas E. Hanlon, Douglas W Heinrichs, Ann Summerfelt, Brian Kirkpatrick, J Levine, Robert W. Buchanan

American Journal of Psychiatry · 1990 · 193 citations · 36 references

Concepts

TL;DR

The study enrolled 116 chronic schizophrenia outpatients in a 2‑year single‑blind trial comparing continuous versus targeted medication, without restricting participants to those suitable for reduction. Continuous medication outperformed targeted medication by reducing decompensations, hospitalizations, and improving employment at 2 years, while other psychopathology and functioning measures were similar and the targeted approach lowered overall medication use.

Abstract

The authors report on the outcome of treatment of 116 outpatients with chronic schizophrenia who were assigned to a 2-year, single-blind course of treatment with either targeted or continuous medication. These patients were not restricted to those who were good candidates for a medication reduction strategy. Continuous medication was superior to targeted medication in preventing decompensations and hospitalizations and in extent of employment at 2 years. Other measures of psychopathology and functioning at 1 and 2 years did not differentiate the two groups of patients. The targeted approach achieved a substantial reduction in total medication through a reduction in the number of days of medication administration.

References

36